Galapagos, Upstate to market adenovirus products

By Elaine Rigoli

Tampa, Fla., May 17 - Galapagos NV announced that its service division, BioFocus, has signed a marketing and sales agreement with Upstate, a wholly owned subsidiary of Serologicals Corp., for Galapagos' adenovirus products worldwide, excluding Japan.

Under the agreement, Upstate will put its manufacturing, marketing, sales, customer support and technical assistance organization behind promotion of Galapagos' adenovirus products, according to a news release.

In return, Galapagos will receive double-digit royalties on net sales achieved by Upstate, the release said.

Galapagos is a genomics-based drug-discovery company based in Mechelen, Belgium.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.